Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Biogen Idec presents new data for multiple sclerosis drugs

Biogen Idec presents new data for multiple sclerosis drugs

19th September 2008

Biogen Idec has announced the presentation of new data on its range of drugs for the treatment of multiple sclerosis.

At the ongoing world congress on Treatment and Research in Multiple Sclerosis taking place this week in Montreal the company will give nearly 20 presentations on its product portfolio in this indication.

It will give new information on Tysabri (natalizumab) and Avonex (interferon beta-1a) as well as other drugs in its research and development pipeline.

These compounds include daclizumab, BG-12 (dimethyl fumarate) and Rituxan (rituximab).

Biogen Idec has also announced that BG-12 has been granted fast track status from the US Food and Drug Administration.

Michael Panzara, vice-president and chief medical officer of neurology at the company, said: “With Tysabri and Avonex, Biogen Idec has provided treatments that have transformed the lives of many patients with MS.”

He added that the company continues to lead the field in the development of treatments for multiple sclerosis with two approved therapies and four in clinical development.

Earlier this month, Elan and Biogen Idec announced the initiation of the first clinical trial of Tysabri in oncology.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.